Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M68,118Revenue $M8,264Net Margin (%)6.2Z-Score2.1
Enterprise Value $M81,801EPS $2.7Operating Margin %20.2F-Score7
P/E(ttm))158Cash Flow Per Share $4.9Pre-tax Margin (%)5.3Higher ROA y-yY
Price/Book15.110-y EBITDA Growth Rate %3.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales8.45-y EBITDA Growth Rate %26.4Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %163ROA % (ttm)1.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)9.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M336ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXJeff Ubben 2014-12-31 Add0.41%$113.56 - $146.39
($134.66)
$ 203.3551%Add 2.43%19,383,877
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 203.3551%New holding, 295632 sh.295,632
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -24.9%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 203.3551%Reduce -18.5%1,378,606
VRXAndreas Halvorsen 2014-12-31 Reduce-0.47%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -8.94%9,077,007
VRXLee Ainslie 2014-12-31 Reduce-0.2%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -4.12%2,423,766
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -0.47%34,331,973
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 203.3551%Reduce -1.19%1,794,227
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 203.3571%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 203.3571%Add 12.4%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 203.3571%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 203.3571%Add 8.89%10,985,940
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 203.3571%Add 32.73%626,748
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 203.3571%Add 11.91%3,529,237
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 203.3571%Add 0.57%34,494,015
VRXAndreas Halvorsen 2014-09-30 Reduce-1.02%$106.73 - $130.26
($118.9)
$ 203.3571%Reduce -15.75%9,967,690
VRXLee Ainslie 2014-09-30 Reduce-0.18%$106.73 - $130.26
($118.9)
$ 203.3571%Reduce -3.7%2,527,896
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 203.3571%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 203.3559%Add 8.19%6,050,442
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRX Joel Greenblatt 2014-12-31295,6320.090.34New Buy
VRX Jean-Marie Eveillard 2014-12-311,191,8320.360.41+17.91%
VRX Jeff Ubben 2014-12-3119,383,8775.7717.4+2.43%
VRX John Paulson 2014-12-31520,7000.160.38
VRX Ruane Cunniff 2014-12-3134,331,97310.2325-0.47%
VRX Chris Davis 2014-12-313,508,1631.051.6-0.6%
VRX Lou Simpson 2014-12-311,794,2270.539.8-1.19%
VRX Private Capital 2014-12-31292,8020.094.6-1.37%
VRX George Soros 2014-12-31606,5870.180.95-3.22%
VRX Lee Ainslie 2014-12-312,423,7660.725.4-4.12%
VRX Glenn Greenberg 2014-12-316,126,6091.8330.5-6.98%
VRX Andreas Halvorsen 2014-12-319,077,0072.76-8.94%
VRX Wallace Weitz 2014-12-311,378,6060.415.5-18.5%
VRX Steve Mandel 2014-12-318,250,8862.465-24.9%
Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4826.71view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0645.19view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.7339.54view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7339.54view
Farmer, RonDirector 2014-11-24Buy1,000$163.9524.03view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.9524.03view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2542.95view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.767.09view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.767.09view
Mirovsky, PavelSenior Officer 2014-06-02Sell10,000$131.2554.93view

Press Releases about VRX :

Quarterly/Annual Reports about VRX:

News about VRX:

Articles On GuruFocus.com
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
How Good is Your Argument? Feb 16 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
ValueAct Holdings trades on 2014 Q4 Feb 05 2015 
Jeff Ubben Deals in Only Four Companies in Fourth Quarter Feb 05 2015 
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 01 2015 
Weitz Value Fund Q4 2014 Commentary Jan 26 2015 
New Guru Jana Partners' Newest Stock Buys Jan 22 2015 
Analysts Make Bullish Ratings in Response to Valeant’s Increased 2015 Guidance Jan 12 2015 
Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 

More From Our Partners
QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Mar 2 2015 - ZACKS

More From Other Websites
JANA Partners ups position in Valeant Pharmaceuticals Mar 02 2015
Updates, advisories and surprises Mar 02 2015
Salix swings to much-wider-than-expected loss as sales plummet Mar 02 2015
Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Management’s Top 5 Health Stocks Mar 02 2015
Valeant set for $9.6bn jumbo junk sale Mar 02 2015
QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Mar 02 2015
3 Best Performing Stocks in February - Analyst Blog Mar 02 2015
The Salix–Valeant merger: Basics of Valeant Mar 02 2015
Hedge Fund Stress, Returns, & Risk Mar 02 2015
10-K for Valeant Pharmaceuticals International, Inc. Feb 27 2015
IBD 50 Stocks Outperform; Several Setups Emerge Feb 27 2015
The Salix–Valeant merger: Basics of Salix Pharmaceuticals Feb 27 2015
Rationale of the Salix–Valeant merger Feb 27 2015
JANA eliminates position in Cameron International Feb 27 2015
Compelling Financial Benefit in Valeant's Latest Buy Feb 27 2015
Basics of the Salix–Valeant merger transaction Feb 26 2015
JANA sells stake in Equinix Feb 26 2015
The Salix–Valeant merger will follow a cash tender timeline Feb 26 2015
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point Feb 26 2015
Pharmacyclics considers $19bn sale Feb 25 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK